Immune checkpoint blockade in renal cell carcinoma
PM Rappold, AW Silagy, RR Kotecha… - Journal of surgical …, 2021 - Wiley Online Library
PM Rappold, AW Silagy, RR Kotecha, AA Hakimi
Journal of surgical oncology, 2021•Wiley Online LibraryImmune checkpoint blockade (ICB) is the foundation of current first‐line therapies in patients
with metastatic renal cell carcinoma (mRCC) with the potential for eliciting long‐lasting
remissions. With the expanding arsenal of ICB‐based therapies, biomarkers of response are
urgently needed to guide optimal therapeutic selection. We review the data behind ICB
therapy in RCC, emerging biomarkers of response, and the evolving role of surgery in
patients with mRCC.
with metastatic renal cell carcinoma (mRCC) with the potential for eliciting long‐lasting
remissions. With the expanding arsenal of ICB‐based therapies, biomarkers of response are
urgently needed to guide optimal therapeutic selection. We review the data behind ICB
therapy in RCC, emerging biomarkers of response, and the evolving role of surgery in
patients with mRCC.
Abstract
Immune checkpoint blockade (ICB) is the foundation of current first‐line therapies in patients with metastatic renal cell carcinoma (mRCC) with the potential for eliciting long‐lasting remissions. With the expanding arsenal of ICB‐based therapies, biomarkers of response are urgently needed to guide optimal therapeutic selection. We review the data behind ICB therapy in RCC, emerging biomarkers of response, and the evolving role of surgery in patients with mRCC.
Wiley Online Library